Diadem to Investigate the Activity and Safety of Durvalumab
Status:
Completed
Trial end date:
2019-05-16
Target enrollment:
Participant gender:
Summary
Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic
options.essentially all patients usually progress and die subsequently to a first line
therapyl. There is strong evidence that the immune system is deeply involved in the
biogenesis of MPM and that an imbalance in pro-inflammatory cytokines and exhausted adaptive
T-cell mediated immune response are the main causes of neoangiogenesis, progression and
metastatisation processes.Numerous Phase II-III clinical trials are underway evaluating
Durvalumab either as monotherapy or combination with evidence of activity in a wide range of
solid tumors. Durvalumab has received FDA approval as second line treatment in patients with
locally advanced or metastatic urothelial carcinoma.
Given these prospects for PD-L1 Ab, a Phase II study is proposed in order to evaluate the
activity and safety of Durvalumab in advanced pretreated MPM.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research